Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis
Submission based on positive Phase III trial in which Ultomiris significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile